Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics


Rhythm Pharmaceuticals, Inc. (RYTM)

Today's Latest Price: $18.94 USD

0.97 (-4.87%)

Updated Jun 4 6:55pm

Add RYTM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RYTM Daily Price Range
RYTM 52-Week Price Range

RYTM Stock Price Chart More Charts


RYTM Price/Volume Stats

Current price $18.94 52-week high $25.84
Prev. close $19.91 52-week low $12.99
Day low $18.85 Volume 141,400
Day high $20.04 Avg. volume 235,211
50-day MA $18.12 Dividend yield N/A
200-day MA $20.09 Market Cap 835.10M

Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio


Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.


RYTM Latest News Stream


Event/TimeNews Detail
Loading, please wait...

RYTM Latest Social Stream


Loading social stream, please wait...

View Full RYTM Social Stream

Latest RYTM News From Around the Web

Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.

Rhythm Pharmaceuticals (RYTM) Investor Presentation - Slideshow

The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts | June 3, 2020

Rhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conference in June

Hunter Smith, Interim Chief Executive Officer and Chief Financial Officer, and Murray Stewart, M.D., Chief Medical Officer, will present a corporate overview at 3:00 p.m. ET. Hunter Smith, Interim Chief Executive Officer and Chief Financial Officer, and Murray Stewart, M.D., Chief Medical Officer, will participate in a fireside chat at 3:50 p.m. ET.

Yahoo | May 26, 2020

Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities

Rhythm Pharmaceuticals, Inc. (RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for setmelanotide, an investigational, melanocortin-4 receptor (MC4R) agonist, for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity. The FDA granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 27, 2020.

Yahoo | May 13, 2020

Rhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference

Rhythm Pharmaceuticals, Inc. (RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Interim Chief Executive Officer and Chief Financial Officer of Rhythm, and, Murray Stewart, M.D., Chief Medical Officer of Rhythm, will participate in a fireside chat at the 2020 BofA Securities Health Care Conference on Tuesday, May 12, 2020 at 8:20 a.m. ET. A live audio webcast of the presentation will be available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. Rhythm is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic dis...

Yahoo | May 5, 2020

Rhythm Pharmaceuticals Reports First Quarter 2020 Financial Results

Rhythm Pharmaceuticals, Inc. (RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today reported financial results and provided a business update for the first quarter ended March 31, 2020. “We are excited about the completion of our first New Drug Application (NDA) submission, which marks a critical next step towards bringing a potentially life-changing medicine to individuals living with rare genetic disorders of obesity,” said Hunter Smith, interim Chief Executive Officer and Chief Financial Officer of Rhythm.

Yahoo | May 4, 2020

Read More 'RYTM' Stories Here

RYTM Price Returns

1-mo -3.07%
3-mo 4.93%
6-mo -22.41%
1-year -21.28%
3-year N/A
5-year N/A
YTD -17.51%
2019 -14.58%
2018 -7.50%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7817 seconds.